Page 1753 - Hematology_ Basic Principles and Practice ( PDFDrive )

1558 Part IX Cell-Based Therapies

an appropriate donor, eliminates the risk of GVHD, and in some Laufs S, Nagy KZ, Giordano FA, et al: Insertion of retroviral vectors in
cases reduces the intensity of preparative regimen required before NOD/SCID repopulating human peripheral blood progenitor cells
transplant, which also reduces toxicity. Thus, in some diseases, this occurs preferentially in the vicinity of transcription start regions and in
therapeutic approach can now be considered an alternative to stan- introns. Mol Ther 10:874–881, 2004.
dard therapy. Insertional mutagenesis, which has resulted in serious Li Z, Dullmann J, Schiedlmeier B, et al: Murine leukemia induced by
adverse events in several trials, has stimulated rapid development of retroviral gene marking. Science 296:497, 2002.
putative safer vector systems that are being tested in human trials but Milsom M, Schambach A, Williams DA, et al: Chemoprotective gene
remains a challenge. Rapid progress in molecular technology, such as delivery. In Harington KJ, Vile RG, Pandha H, editors: Viral therapy of
high-throughput sequencing and the development of new sources of cancer, Indianapolis, IN, 2008, Wiley Press, pp 376–391.
expandable stem cell sources, offers significant potential for ongoing Miyoshi H, Smith KA, Mosier DE, et al: Transduction of human CD34(+)
development of gene transfer in regenerative biology for a wide range cells that mediate long-term engraftment of NOD/SCID mice by HIV
of human conditions. vectors. Science 283:682–686, 1999.
Moritz T, Patel VP, Williams DA: Bone marrow extracellular matrix molecules
improve gene transfer into human hematopoietic cells via retroviral
ACKNOWLEDGEMENTS vectors. J Clin Invest 93:1451–1457, 1994.
Naldini L, Blomer U, Gallay P, et al: In vivo gene delivery and stable trans-
Funding from NIH DK062757, CA113969, AI097628, DK090913, duction of nondividing cells by a lentiviral vector. Science 272:263–267,
and the NHLBI Gene Therapy Resource Program. I would like to 1996.
thank members of my laboratory and members of the Transatlantic Ott MG, Stein S, Schultze-Strasser S, et al: Phase I/II gene therapy study for
Gene Therapy Consortium for productive collaborations. Chronic Granulomatous Disease: results, lessons and perspectives. Blood
(ASH Annual Meeting Abstracts) 110:503, 2007.
Pai S, Notarangelo L, Harris C, et al: Somatic gene therapy for X-linked
SUGGESTED READINGS severe combined immunodeficiency using a self-inactivating modified
gammaretroviral vector results in an improved preclinical safety profile
Aiuti A, Cassani B, Andolfi G, et al: Multilineage hematopoietic reconstitu- and early clinical efficacy in a human patient. Blood (ASH Annual Meeting
tion without clonal selection in ADA-SCID patients treated with stem Abstracts) 118:164, 2011.
cell gene therapy. J Clin Invest 117:2233–2240, 2007. Park IH, Zhao R, West JA, et al: Reprogramming of human somatic cells to
Aiuti A, Slavin S, Aker M, et al: Correction of ADA-SCID by stem cell pluripotency with defined factors. Nature 451:141–146, 2008.
gene therapy combined with nonmyeloablative conditioning. Science Porteus MH, Carroll D: Gene targeting using zinc finger nucleases. Nat
296:2410–2413, 2002. Biotechnol 23:967–973, 2005.
Bauer TR, Jr, Allen JM, Hai M, et al: Successful treatment of canine leukocyte Sadelain M, Papapetrou EP, Bushman FD: Safe harbours for the integration
adhesion deficiency by foamy virus vectors. Nat Med 14:93–97, 2008. of new DNA in the human genome. Nat Rev Cancer 12:51–58, 2012.
Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al: Hematopoietic stem Sankaran VG, Menne TF, Xu J, et al: Human fetal hemoglobin expression is
cell gene therapy with a lentiviral vector in X-linked adrenoleukodystro- regulated by the developmental stage-specific repressor BCL11A. Science
phy. Science 326:818–823, 2009. 322:1839–1842, 2008.
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al: Gene therapy of Stein S, Ott MG, Schultze-Strasser S, et al: Genomic instability and myelo-
human severe combined immunodeficiency (SCID)-X1 disease. Science dysplasia with monosomy 7 consequent to EVI1 activation after gene
288:669–672, 2000. therapy for chronic granulomatous disease. Nat Med 16:198–204, 2010.
Cavazzana-Calvo M, Payen E, Negre O, et al: Transfusion independence Takahashi K, Tanabe K, Ohnuki M, et al: Induction of pluripotent stem cells
and HMGA2 activation after gene therapy of human beta-thalassaemia. from adult human fibroblasts by defined factors. Cell 131:861–872, 2007.
Nature 467:318–322, 2010. Thrasher AJ, Gaspar HB, Baum C, et al: Gene therapy: X-SCID transgene
Gaspar HB, Parsley KL, Howe S, et al: Gene therapy of X-linked severe leukaemogenicity. Nature 443:E5–E6, discussion E6-E7, 2006.
combined immunodeficiency by use of a pseudotyped gammaretroviral Urnov FD, Miller JC, Lee YL, et al: Highly efficient endogenous human gene
vector. Lancet 364:2181–2187, 2004. correction using designed zinc-finger nucleases. Nature 435:646–651,
Hacein-Bey-Abina S, Le Deist F, Carlier F, et al: Sustained correction of 2005.
X-linked severe combined immunodeficiency by ex vivo gene therapy. N Williams DA, Thrasher AJ: Concise review: lessons learned from clinical
Engl J Med 346:1185–1193, 2002. trials of gene therapy in monogenic immunodeficiency diseases. Stem Cells
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al: LMO2-associated Transl Med 3:636–642, 2014.
clonal T cell proliferation in two patients after gene therapy for SCID-X1. Xu J, Peng C, Sankaran VG, et al: Correction of sickle cell disease in
Science 302:415–419, 2003. adult mice by interference with fetal hemoglobin silencing. Science
Hanna J, Wernig M, Markoulaki S, et al: Treatment of sickle cell anemia 334:993–996, 2011.
mouse model with iPS cells generated from autologous skin. Science Yu J, Vodyanik MA, Smuga-Otto K, et al: Induced pluripotent stem cell
318:1920–1923, 2007. lines derived from human somatic cells. Science 318:1917–1920, 2007.
Hirschhorn R, Yang DR, Puck JM, et al: Spontaneous in vivo reversion to
normal of an inherited mutation in a patient with adenosine deaminase
deficiency. Nat Genet 13:290–295, 1996. REFERENCES
Howe SJ, Mansour MR, Schwarzwaelder K, et al: Insertional mutagenesis
combined with acquired somatic mutations causes leukemogenesis fol- For the complete list of references, log on to www.expertconsult.com.
lowing gene therapy of SCID-X1 patients. J Clin Invest 118:3143–3150,
2008.